At Pulmatrix, we are committed to communicating clear and consistent information. Here we feature current and historic content concerning our science, our pipeline, and our corporate initiatives and achievements. Please check in often for the most recent press releases and information.
May 5, 2016
Pulmatrix, Inc. (NASDAQ: PULM) today reports its first quarter financial results and provides an update on the progress of its drug development pipeline. "During the first quarter, we continued to...
Apr 19, 2016
Writing in ONdrugDelivery Magazine, CSO David L. Hava describes how innovative new strategies for delivering inhaled drugs to the lungs can fight serious bacterial and fungal infections.
Pulmatrix, Inc. (NASDAQ: PULM) announced today that its Chief Scientific Officer, David L. Hava, PhD, has written an article in ONdrugDelivery Magazine highlighting advances in delivering drugs to...
Mar 10, 2016
2015 was a transformational year - lead assets for COPD and cystic fibrosis continue to progress in clinical development.
Pulmatrix, Inc. (NASDAQ: PULM) today announces 2015 financial results, reviews the Company's recent progress, and provides an outlook for 2016 for its pulmonary disease development pipeline. "2015...
Mar 10, 2016
Dear Fellow Shareholders, Continuing our Momentum As Pulmatrix moves into 2016, we wanted to describe to our shareholders the significant progress the Company is making—and how...
Mar 4, 2016
CEO Clarke to provide update on PULM business activities
Pulmatrix, Inc., (NASDAQ: PULM) will present a business update at the Cowen and Company 36th Annual Health Care Conference on Wednesday, March 9th at 11:20 am EST (8:20 am PST). A live webcast of...